Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients

NCT03141203 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Peripheral T Cell Lymphoma

Interventions

DRUG: Romidepsin
DRUG: Carfilzomib

Sponsor

University of Birmingham

Collaborators

[object Object]
[object Object]
[object Object]